NABRIVA THERAPEUTICS AG (NASDAQ:NBRV) Files An 8-K Results of Operations and Financial ConditionItem 2.02 below.
Item 2.02 Results of Operations and Financial Conditions.
On May 10, 2017, Nabriva Therapeutics AG (the “Company”) filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2017 (the “Form 10-Q”). Immediately after the filing of the Form 10-Q, the Company furnished a Current Report on Form 8-K (the “Form 8-K”) disclosing that it had issued a press release announcing its consolidated financial results for the quarter ended March 31, 2017 and including a copy of the press release as an exhibit to the Form 8-K. The Company is furnishing this amendment on Form 8-K/A to the Form 8-K to reflect the correction of inadvertent discrepancies in the financial information disclosed in the tables at the end of the press release as compared to the financial information that was contained in the Form 10-Q. The discrepancies in the press release required a correction of total “Net cash used in operating activities” in the Consolidated Statement of Cash Flows for the three months ended March 31, 2016 and March 31, 2017 (although the components of this total amount were accurately stated in the press release). A copy of the corrected press release is included as Exhibit 99.1 to this Current Report on Form 8-K/A.
The information in this Form 8-K/A, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:
Exhibit 99.1 Corrected press release issued by Nabriva Therapeutics AG, dated May 12, 2017.